Although recent guidelines for managing chronic these, 32 (31%) were unresponsive to salbutamol and prednisolone; 48 (46%) were responsive to obstructive pulmonary disease (COPD) recommend a trial of oral corticosteroids in the initial assessbeta agonists but not to corticosteroids, and 24 (23%) responded to corticosteroids and salbutamol. ment, its prognostic value remains unclear. We prospectively studied 127 adults (64% men) with stable
Introduction
Chronic obstructive pulmonary disease (COPD) is an and a reduction in the subsequent rate of decline. Bronchodilator response is not particularly sensitive important cause of morbidity and mortality in the USA and elsewhere.3 Symptomatic bronchodilator in identifying such patients. 6 In a study of patients with COPD, lung function improved modestly over therapy is a cornerstone of COPD management, and an objective assessment of this treatment is recoma 1-year period in those treated with inhaled corticosteroids.7 It is not known if such responses can be mended in all patients.1,2,4 In contrast, the role of corticosteroids orally or by inhalation remains conpredicted, nor even whether they can be expected, in more severe COPD. tentious. One large meta-analysis estimated that 10% of stable COPD patients responded to a 2-week oral
We have previously shown that almost 40% of patients with stable moderate and severe COPD have corticosteroid trial.5 Retrospective studies of COPD patients taking oral prednisolone suggest that some a bronchodilator response to a two-week trial of corticosteroids.8 However, it was not possible to patients show initial improvement in lung function differentiate oral corticosteroid responders from nonpolicies in response to the results. Both advised that patients with a positive corticosteroid trial received responders at presentation, since the two groups of patients presented with similar symptoms, suggesting inhaled beclomethasone dipropionate through a metered dose inhaler (with or without a spacer, that the 'responsive' patients were not merely a subgroup of asthmatics. The aim of this study was depending upon the ability of the patient to use the MDI appropriately) as 800 mcg daily in divided to investigate if patients with stable moderate-tosevere COPD who have an improvement in spirodoses. Physician A's policy was to give the same treatment to all other patients irrespective of metry after a steroid trial and are subsequently treated with inhaled steroids have improved lung function their bronchodilator responses, whilst physician B restricted inhaled corticosteroid treatment to those and improved symptoms after 1 year follow-up, compared to non responders.
with a positive corticosteroid trial. Patients were reviewed 3-monthly, when smoking cessation and compliance with treatment were encouraged and inhaler technique was checked.
Methods
All patients were invited to return for visit 3 at 1 year after their initial assessment when the question-
Patients
naire and salbutamol reversibility test were repeated. The corticosteroid challenge was not repeated. Participants in this study were drawn from an initial cohort of 127 patients previously described,8 who
Patients were asked the same questions on the presence or absence of symptoms such as cough met the ATS definition of COPD4 and had been seen consecutively as new referrals to our out-patient and sputum, and on treatment actually taken, and a VAS of symptom severity was repeated. Medical staff department. All had clinically stable COPD, defined by a history of progressive continuous breathlessness recording the data were unaware of the results of the initial investigations. Each patient gave informed of at least 1 year duration and documented airflow limitation (FEV 1 /FVC <60%). Patients with cardiac consent to the study, which was approved by the hospital ethical committee. or other pulmonary disorders, including documented asthma, were excluded. Asthma was excluded on All spirometric assessments were performed on the same water spirometer (PK Morgan, Rainham, the basis of symptoms of intermittent wheeze and breathlessness, history of atopy or previous physician Kent). The staff collecting the data were unaware of the patients' physician, initial spirometry or subdiagnosis. None of the patients had had an acute exacerbation or received oral corticosteroids within sequent treatment. The best FEV 1 and FVC from three technically acceptable tracings were recorded.9 The 3 months of assessment. Those entering this study had been taking ∏200 mcg beclomethasone or salbutamol was nebulized using a System 22 nebulizer powered by oxygen at 5 l/s. Post bronchodilator equivalent, and/or had used this for less than 1 month before assessment and/or had not complied measurements were recorded 15 min after the nebulization ended. with their treatment.
Each patient attended the laboratory three times, A significant change in lung function was defined as a change in FEV 1 that was both 15% or more of and was asked to omit inhaled bronchodilators for 6 h and oral bronchodilators for 24 h beforehand. At the baseline value and greater or equal to 200 ml. This allows for the spontaneous variability of the the first visit, a respiratory symptom questionnaire was administered and a subjective assessment of FEV 1 between repeated measurements10 and encompasses both the European Respiratory Society's11 and overall symptom severity was recorded on a 10 cm visual analogue scale (VAS). Spirometry before and American Thoracic Society's criteria for a bronchodilator response. after 5 mg nebulized salbutamol was also performed. Helium dilution lung volumes and carbon monoxide transfer factor were measured before the broncho-
Statistical analysis
dilator test, and skin prick tests to five common allergens and an eosinophil count were done. The
Statistical comparisons between group data were made using ANOVA for normally distributed data or patient was prescribed a 2-week course of oral prednisolone, 30 mg per day, and returned for a else by non-parametric Wilcoxon rank sum tests. To make allowance for the use of multiple comparisons, further prebronchodilator FEV 1 at its conclusion. The results of both types of reversibility testing we used the Bonferroni correction. As our study did not contain an initial control group, we calculated a were available to the referring physicians. The patients were referred by one of two physicians and treatment effect size using the method suggested by Kazis12 and the formula: effect size=(X2-X1)/SD, allocated in a random order to the laboratory staff, who performed the tests without knowledge of their where X2 is the mean post-bronchodilator FEV 1 value and X1 the mean pre-bronchodilator value. The source. The referring physicians adopted different standard deviation (SD) chosen is the SD of the There were no differences in spirometry and symptoms between these two groups. baseline pre or post-bronchodilator FEV 1, as appropriate. Correlations between data used the least Over the year, group mean FEV 1 rose from 0.88 (0.26) to 1.29 (0.58) l in the corticosteroid and squares method. Comparisons between baseline spirometry at visits 1 and 3 were made using the bronchodilator responsive patients (group 3, Table 2 ). The larger the initial response to prednisolone, the method of Bland and Altman to reduce the risk of auto-correlation.13 Data are expressed as means±SD greater was the chance that the baseline FEV 1 would be higher at 1 year; especially in subjects whose unless otherwise stated.
initial change in FEV 1 after an oral corticosteroid trial was at least 400 ml (Figure 1) . In four patients the FEV 1 at 1 year was equivalent to that after their
Results
initial course of oral prednisolone, and these patients showed no further bronchodilation with beta Follow-up data at visit 3 were available in 104 (82%) of the original 127 patients, and all subsequent data agonists. Eighteen patients still showed significant increases in FEV 1 after beta agonist at 1 year (mean relate to these patients. Of the 23 not followed-up, three had died, five had moved away from the area, initial change 0.57 l; mean change at 1 year 0.42 l). The remaining six patients, (mean FEV 1 0.88 l (0.18)) and two were on regular maintenance oral corticosteroids. The remaining 13 were contacted but showed a smaller initial change with prednisolone (mean change in FEV 1 0.46 vs. 0.87 l; p<0.05) and declined to attend. Of these 127 patients, 64% were male and 93% had smoked cigarettes. The mean a smaller increase in baseline FEV 1 at 1 year (FEV 1 0.88 (0.18) l initially; 1.18 (0.32) l at follow-up). each group over the year of follow-up. The presence Patients were divisible into three groups by bronof specific clinical features, e.g. sputum production, chodilator response. Thirty-two (31%) were unrewheeze, or laboratory findings, e.g. atopy, blood sponsive to salbutamol at either visits 1 or 3 and to eosinophilia, did not accurately predict those patients prednisolone at visit 1 (group 1). Forty-eight (46%) whose baseline or post-bronchodilator FEV 1 subwere corticosteroid-unresponsive but salbutamolsequently improved. This was true irrespective of responsive (group 2). Twenty-four (23%) had a positthe physician managing the patient. Likewise, the ive bronchodilator response to corticosteroids and change in FEV 1 after nebulized salbutamol was also had a bronchodilator response to salbutamol unhelpful, but the response to two weeks oral (group 3). prednisolone was correlated with subsequent baseThe characteristics of these patients at study entry line FEV 1 (Spearman coefficient; r=0.60, p<0.01) are shown in Table 1 . The steroid responders had a (Figure 3a, b) . higher mean eosinophil count ( p<0.001), were
The effect size for changes in baseline FEV 1 for more likely to be ex-smokers ( p<0.0001) and had the whole group was 0.28 using the prea significantly higher DLCO ( p<0.001). The changes bronchodilator FEV 1 and 0.15 using the postin symptoms, lung function and drug therapy over bronchodilator FEV 1 . This change was due almost the 1-year period are summarized in Table 2 . These entirely to patients in group 3 who had shown an will be considered for each group in turn. initial positive oral corticosteroid trial. Symptoms, spirometry and bronchodilator reversibility were unchanged over the year despite bronchodilator-unresponsive patients receiving more treatment (group 1, Table 2 ). Similarly, symptoms Discussion and spirometry (either before or after bronchodilator) did not change over the year in the corticosteroidThe purpose of this study was to assess the longterm value, if any, of FEV 1 response to an oral unresponsive but bronchodilator-responsive patients (group 2, Table 2 ). Thirty-five of the 80 patients in corticosteroid trial in patients with moderate and severe stable COPD. The results of our study indicate groups 1 and 2 were treated with inhaled corticosteroids over the period between visit 2 and visit 3.
that a subset of patients with stable COPD who have inhaled corticosteroids have an improved clinical course and improved lung function. Our results also suggest that patients with COPD have a variable response in these patients does not indicate better lung function or symptoms at 1 year follow-up. response to high-dose inhaled beta agonists over time, and that the presence of a bronchodilator This study followed carefully-defined consecutive COPD patients.14 The existence of a corticosteroidand bronchodilator-responsive subset in COPD has some theoretical support. Recent biopsy studies have confirmed the presence of inflammatory cell infiltrates including T lymphocytes in bronchial biopsies from COPD patients.15 Amongst COPD patients with equivalent reductions in FEV 1 , those with relatively less emphysema had more eosinophils in their airways and had exhibited greater bronchodilator responses during life.16,17 The physiological course of our corticosteroid-responsive group is compatible with some, or all, of the above processes.
We tested with a higher dose of beta agonist than in the IPPB study to ensure that we were high on the plateau of the dose-response relationships for bronchodilators.18 Previously we have found little difference between beta agonists and ipratropium in defining a bronchodilator response at these concentrations. 19 We deliberately chose a wide range of bronchodilator responses as an entry criteria, unlike either of the current prospective trials of inhaled corticosteroids in COPD (EUROSCOP/ISOLDE), as our study was a clinical one and we did not wish to censor our data. The absence of a placebo/ corticosteroid trial has limited the conclusions we can draw, but such studies cannot easily be applied to patient care as they have a cross-over and order effect. 20 We used FEV 1 as our principal outcome the IPPB study, we found short-term bronchodilator responses to be quite variable among the corticosteroid non-responders, with 13 moving from nonpatients with COPD over 1 year. We were particularly anxious to exclude any patients who may have responder to responder and 18 from responder to non-responder when reviewed at 1 year. The clinical asthma as the underlying cause of their COPD. Most patients were smokers and had symptoms of COPD, characteristics and subsequent course of any of these subgroups were identical, and variability is likely and all patients were all screened for a personal history of asthma. Despite our careful exclusion of to reflect differences in baseline cholinergic tone, reflected in the starting FEV 1 .21 As noted above, beta asthma, the patients who were subsequently found to be steroid-responsive had significantly higher agonist reversibility in the corticosteroid responders is harder to interpret, as some may already have eosinophil counts and more positive skin tests. Thus it is possible that some of the steroid-responding reached the maximum airway calibre that they can achieve anatomically, and will therefore be unable patients were in fact asthmatic. We believe this unlikely as all had had significant cigarette exposure, to bronchodilate further. Variations in underlying disease, response to or compliance with treatment none had symptoms typical of asthma, all had significant post bronchodilator and post-corticomay explain why some patients still have residual bronchodilator responses without changing their steroid pulmonary function impairment, there was no excess of atopy in the group 3 patients and baseline FEV 1 at 1 year. Changes in smoking and treatment had little effect although their peripheral blood eosinophil count was more likely to be elevated, these data were not on the course of the illness. This could reflect different susceptibility, the relatively small numbers individually predictive. In the absence of biopsy evidence to confirm asthmatic features, we consider in each group, or the duration of follow-up. Although the study size is comparatively small, the results of it more likely that these patients represent a subset of COPD patients. Burrows et al. have described this study also seem to suggest that only those patients with a positive oral corticosteroid response patients with 'asthmatic bronchitis' who have blood eosinophilia and a more benign prognosis than other have a sustained improvement in pulmonary function symptoms and brochial hyper-reactivity in patients with compared to non-responders subsequently treated non-asthmatic chronic airflow obstruction. is clinically useful in stable COPD patients. How-27:S178-S189.
ever, the interpretation of individual corticosteroid
